Eichenbaum Acorns

Andrea Gibson, PhD, and Erin C. Henry, PhD, trace 20 years in retina drug development—and the pathway gap still facing young scientists.

A former US Navy flight surgeon turned three-time CMO, David J. Tanzer, MD, ABO, reflects on a career built at the pharma-clinic bridge.

For Caroline R. Baumal, MD, a path from academic retina through industry leadership has brought her full circle—back to the clinic with a broader view of the field.

For Jay S. Duker, MD, and Ramiro Ribeiro, MD, PhD, paths that began in clinical and academic medicine became the foundation for a different kind of work—leading drug development from the inside.

From role models to open doors, Christina Y. Weng, MD, MBA, FASRS, shares insights on career development, women in ophthalmology, evolving training models, and her work as protocol chair for the DRCR Retina Network’s Protocol AO study.

For Jeffry D. Gerson, OD, FAAO, an early fascination with retinal disease—sparked during residency and shaped by mentorship and emerging OCT technology—led to a career focused on education and OD-MD collaboration.

When no retina podcast was available, Jayanth Sridhar, MD, created one—and learned lessons about branding, bandwidth, and mentorship along the way.

For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice.

Behind the scenes of building impactful educational platforms in retina care